Cost-Effectiveness Analysis for the Treatment of Diabetic Foot Ulcer in France: Platelet-Rich Plasma vs Standard of Care
Salvatore Russo,Stefano Landi,Stephane Courric
DOI: https://doi.org/10.2147/CEOR.S327191
2022-01-04
ClinicoEconomics and Outcomes Research
Abstract:Salvatore Russo, 1, &ast Stefano Landi, 2, &ast Stephane Courric 3 1 Department of Management, University of Venice, Venezia, Italy; 2 Department of Business Administration and Management, University of Verona, Verona, Italy; 3 Hays Pharma, Paris, France &astThese authors contributed equally to this work Correspondence: Stefano Landi Department of Business Administration and Management, University of Verona, Via Cantarane, 24, Verona, 37129, Italy Tel +39 3463287572 Email Introduction: Diabetic chronic foot ulcers (DFU) lead to pain, reduced quality of life and represent a severe economic burden for patients and health systems. The clinical results of PRP effectiveness in the treatment of DFU are promising; on the other hand, the costs associated with treating DFUs with PRP are higher than those using standard therapy. Therefore, this study aims to determine the cost-effectiveness of platelet-rich plasma (PRP) therapy compared to standard therapy from the French healthcare system perspective. Methods: A cost-effectiveness analysis (CEA) was performed using a decision Markov model with a cohort of patients with chronic DFU (duration of > 3 weeks) with high orthopaedic risk and with ulcers graded 3A according to University of Texas classification. The effectiveness outcomes are reported in terms of quality adjusted life year (QALY). The costs are reported in euro (€) currency evaluated in 2019. A micro-costing approach alongside a clinical study was used to assess resource use. Deterministic sensibility analyses are reported to evaluate the robustness of the results. The analyses were carried out in the French setting. Results: The incremental cost-effectiveness ratio (ICER) of PRP treatment is –€ 613/ QALY, which, being lower than zero, indicates the dominance of the PRP therapy. Deterministic and probabilistic sensitivity analysis underlines the main parameter affecting CE results. Lowest number of standard of care weekly medications (from 5 to 3) leads to a € 622/QALY while increasing PRP weekly medication (from 1 to 4) has an ICER of € 732/QALY. Discussion: PRP is a cost-effective or even a cost-saving alternative in the French setting. PRP has higher cost for the complete medication, but, in the absence of wound complications, has the potential to involve lower consumption of resources in the form of routine medication over a 1-year time horizon. Keywords: platelet-rich plasma, cost-effectiveness analysis, cost-utility analysis, diabetic foot ulcer Chronic non-healing ulcer is a major health problem and its prevalence in the world ranges from 1.9 to 13.1%. 1,2 The incidence of chronic ulcers is expected to increase as the population ages and the risk factors for atherosclerotic occlusion such as smoking, obesity and diabetes are increasing. One of the main causes of non-healing ulcer is diabetes. Diabetic foot ulcer (DFU) is diagnosed in 12–18% of patients with type 2 diabetes and in 0.6–2% of patients with type 1 diabetes. 3 In addition, 70% of these patients are diagnosed with peripheral neuropathy. 4,5 Diabetic chronic wounds lead to pain, discomfort, infection, consultations, dressings, hospitalizations, sequelae, sick leave, and poor quality of life. Individuals with diabetic foot ulcers are susceptible to infection and the healing process is complicated by diabetic neuropathy leading to chronic non-healing ulcers. Consequently, an estimated 12% of individuals with diabetic foot ulcer require lower extremity amputation. 3,8,9 Moreover, chronic ulcers also represent a substantial financial burden for the patient and the healthcare system. 6,7 The Eurodiale study analysed the direct and indirect annual costs in several European countries (in 14 European centres including Spain, France, the UK, Czech Republic, Germany, Denmark, Sweden and Italy) with a total of 821 patients with DFU. The mean annual cost per patient was €10,091, hospitalization being the most relevant direct cost. 10 In the UK, the mean NHS cost of wound care over 12 months was estimated at £7800 per DFU (of which 13% was attributable to amputations), ranging from £2140 to £8800 per healed and unhealed DFU, respectively, and £16,900 per amputated wound. 11 The main element (around 20%) of total spending is complications related to DFU. 12 In the US, DFU accounted for 83% and 96% of all major and minor amputations related to foot ulcers, respectively, and significantly increased cost of care (DFU: 0.13 billion/year; p <0.001). 13 Therefore, it is important to evaluate strategies that can ensure better prevention and management -Abstract Truncated-